Michael Byrne
Medical Director, Cellular Therapy OneOncology
Dr. Byrne is a malignant hematologist at Tennessee Oncology. He has led the successful launch of Tennessee Oncology’s cellular therapy program that has expanded access for Tennessee cancer patients to an advanced cellular therapy, known as CAR-T cell therapy. Tennessee Oncology is one of the first practices to deliver CAR-T cell therapy in the community setting.
Seminars
Wednesday 15th July 2026
Panel Discussion: Building Sustainable CAR-T Access Through Community Oncology Engagement
3:30 pm
- Why community oncology is critical to scaling CAR-T and building infrastructure for long-term patient access
- Key operational and financial differences between academic and community sites that impact market entry
- How reimbursement timelines, coverage policies, and financial risk influence community adoption of high-cost cell therapies
